More than a year after announcing plans to spin out its drug business, Baxter has begotten Baxalta, a $6 billion standalone company with plans to elbow its way into the upper ranks of biopharma.

…read more

Source: Baxalta sets sail with blockbuster ambitions for its growing pipeline


0 No comments